New pill shows promise in battling advanced kidney cancer
NCT ID NCT05119335
First seen Nov 12, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This trial tested an oral drug called NKT2152 in 120 people with advanced clear cell kidney cancer that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The study was stopped early, but results may help guide future treatments for this type of cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
National Cancer Institute
Bethesda, Maryland, 20892-9760, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73117, United States
Conditions
Explore the condition pages connected to this study.